Document Detail

Therapy with statins in patients with refractory rheumatic diseases: a preliminary study.
MedLine Citation:
PMID:  12945719     Owner:  NLM     Status:  MEDLINE    
We have explored the therapeutic potential of statins in patients with different inflammatory rheumatic diseases refractory to conventional therapy. We found that simvastatin (80mg o.d. for eight days) induced a rapid and significant reduction in proteinuria levels in three systemic lupus erythematosus (SLE) patients. A similar kind of therapy had a marked beneficial effect in a patient with Wegener's granulomatosis and a patient with erythema nodosum. On the other hand, five patients with rheumatoid arthritis (RA) who received atorvastatin for eight days (20mg/day) showed reduction in C-reactive protein levels and a clinical improvement that was classified as an ACR20 response. Prior to the administration of statins, all these patients had received aggressive conventional therapy with no satisfactory response. A significant reduction in spontaneous apoptosis of peripheral blood lymphocytes and expression of CD69 and HLA-DR was observed in SLE patients after simvastatin therapy. These results prompted us to perform a pilot short-time comparative (simvastatin versus chloroquine) open clinical trial in 15 patients with RA who were receiving methotrexate as a single disease modifying antirheumatic drug with no satisfactory response. Most patients (9/10) who received simvastatin (40mg/day) showed an ACR50 or better response after eight weeks, whereas such a response was not observed in any patient (0/5) treated with chloroquine. Our preliminary results indicate that statins may be an important therapeutic tool for the treatment of inflammatory rheumatic diseases.
C Abud-Mendoza; H de la Fuente; E Cuevas-Orta; L Baranda; J Cruz-Rizo; R González-Amaro
Related Documents :
24487699 - Further evidence about the crucial role of csf biomarkers in diagnosis of posterior cor...
24014979 - Anterior orbit and adnexal amyloidosis.
20092399 - Increased expression of proto-oncogene survivin predicts joint destruction and persiste...
8057669 - N-ras mutation and karyotypic evolution are closely associated with leukemic transforma...
16606409 - Association of hla subtype drb10407 in colombian patients with actinic prurigo.
1282009 - Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with va...
21883879 - The timing, extent, progression and regression of deep vein thrombosis in immobile stro...
1574999 - Pseudoseizures--risk factors and prognosis. a case-control study.
11587989 - Interleukin-4 and its alternatively spliced variant (il-4delta2) in patients with atopi...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Lupus     Volume:  12     ISSN:  0961-2033     ISO Abbreviation:  Lupus     Publication Date:  2003  
Date Detail:
Created Date:  2003-08-29     Completed Date:  2005-02-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9204265     Medline TA:  Lupus     Country:  England    
Other Details:
Languages:  eng     Pagination:  607-11     Citation Subset:  IM    
Unidad Regional de Reumatología y Osteoporosis, Hospital Central, San Luis Potosí, Mexico.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antirheumatic Agents / therapeutic use
Biological Markers / blood
Blood Sedimentation / drug effects
C-Reactive Protein / drug effects,  metabolism
Chloroquine / therapeutic use
Dose-Response Relationship, Drug
HLA-DR Antigens / drug effects,  metabolism
Heptanoic Acids / therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage,  adverse effects,  therapeutic use*
Leukocytes, Mononuclear / drug effects
Lupus Erythematosus, Systemic / drug therapy,  metabolism
Middle Aged
Proteinuria / chemically induced,  metabolism
Pyrroles / therapeutic use
Rheumatic Diseases / drug therapy*,  metabolism
Rheumatic Fever / drug therapy,  metabolism
Simvastatin / therapeutic use
Treatment Outcome
Wegener Granulomatosis / drug therapy,  metabolism
Reg. No./Substance:
0/Antirheumatic Agents; 0/Biological Markers; 0/HLA-DR Antigens; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 110862-48-1/atorvastatin; 54-05-7/Chloroquine; 79902-63-9/Simvastatin; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as...
Next Document:  Reversible acute gastrointestinal syndrome associated with active systemic lupus erythematosus in pa...